Therakind patents expiration

1. Jylamvo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11129833 THERAKIND Methotrexate formulation
Oct, 2035

(12 years from now)

Drugs and Companies using METHOTREXATE ingredient

Market Authorisation Date: 29 November, 2022

Treatment: NA


More Information on Dosage

JYLAMVO family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic